Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01383759 · OUTCOME

Participants Evaluated for Toxicity

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis · Source last updated 2020-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years

What was measured

Toxicities will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.

Groups in this outcome

Amyloidosis

Participants with newly diagnosed AL amyloidosis

Monoclonal Ig DepositionDisease (MIDD)

Participants with newly diagnosed Monoclonal Ig DepositionDisease (MIDD)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Amyloidosis19
Monoclonal Ig DepositionDisease (MIDD)1

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Amyloidosis19Not reportedNot reportedNot reportedNot reported
Monoclonal Ig DepositionDisease (MIDD)1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        19
      2. group Id
        OG001
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    2. group Id
      OG001
      value
      1
    units
    Participants
description
Toxicities will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.
groups
  1. description
    Participants with newly diagnosed AL amyloidosis
    id
    OG000
    title
    Amyloidosis
  2. description
    Participants with newly diagnosed Monoclonal Ig DepositionDisease (MIDD)
    id
    OG001
    title
    Monoclonal Ig DepositionDisease (MIDD)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
2 years
title
Participants Evaluated for Toxicity
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice